CLINICAL TRIALS PROFILE FOR NADOLOL

All Clinical Trials for NADOLOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	The Hospital for Sick Children	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	University of Utah	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.

Clinical Trial Conditions for NADOLOL

Condition Name

Condition Name for NADOLOL
Intervention	Trials
Heart Failure With Preserved Ejection Fraction	2
Heart Failure, Diastolic	2
Portal Hypertension	2
Infantile Hemangioma	2

Condition MeSH

Condition MeSH for NADOLOL
Intervention	Trials
Hypertension	5
Hemorrhage	4
Migraine Disorders	3
Liver Cirrhosis	3

Clinical Trial Locations for NADOLOL

Trials by Country

Trials by Country for NADOLOL
Location	Trials
United States	34
Canada	6
Spain	2
China	1
Puerto Rico	1

Trials by US State

Trials by US State for NADOLOL
Location	Trials
Ohio	4
New York	3
Missouri	3
North Carolina	2
Virginia	2

Clinical Trial Progress for NADOLOL

Clinical Trial Phase

Clinical Trial Phase for NADOLOL
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	3
Phase 2	4

Clinical Trial Status

Clinical Trial Status for NADOLOL
Clinical Trial Phase	Trials
Completed	14
Unknown status	4
Enrolling by invitation	2

Clinical Trial Sponsors for NADOLOL

Sponsor Name

Sponsor Name for NADOLOL
Sponsor	Trials
National Science Council, Taiwan	3
Invion, Inc.	3
The Hospital for Sick Children	3

Sponsor Type

Sponsor Type for NADOLOL
Sponsor	Trials
Other	24
Industry	11
NIH	3

Nadolol Clinical Trials Update and Market Outlook

Last updated: April 27, 2026

What is nadolol and where does it sit today?

Nadolol is an older, non-selective beta-adrenergic blocker (beta-1 and beta-2 antagonist) used for cardiovascular indications and historically for certain off-label uses. It is widely available as a generic product in multiple jurisdictions, which materially limits near-term pricing power and shifts market expectations toward volume, manufacturing cost, and formulary access rather than novel therapeutic differentiation.

Established positioning (commercial reality)

• Regulatory status: Nadolol is an approved medicine with extensive generic entry in most major markets (i.e., typical branded exclusivity periods have long expired).
• Implication for clinical pipeline: Most activity around nadolol is likely to be incremental (new formulations, bioequivalence, label updates, combination products) rather than first-in-class trials, because the active is not patent-protected in most countries.

What clinical trial activity exists for nadolol now?

No complete, current-trial dossier (with dates, study identifiers, phase, endpoints, and enrollment status) is available in the provided context. Under the operating constraints, this prevents a complete and accurate “clinical trials update” with verifiable specifics.

Where does nadolol generate revenue today (and what drives demand)?

With nadolol’s age and broad generic availability, demand drivers skew toward prevalence and prescribing habits rather than innovation:

• Indication burden and use patterns: Patients requiring non-selective beta blockade (and prescribers favoring nadolol over alternatives) drive baseline volume.
• Substitution within the class: Non-selective beta blockers (e.g., propranolol) and other beta blockers compete. In many systems, prescribers balance efficacy history, dosing convenience, and patient-specific tolerability.
• Access and price compression: Generic nadolol prices tend to track manufacturing and competitive tender dynamics, limiting upside without differentiation or supply stability advantages.
• Formulary decisions: Hospital formularies and outpatient formularies can move demand across molecules within the class, even if clinical endpoints are similar.

Market sizing and projection: what can be projected?

A defensible market projection requires at least one of the following: (i) current market revenues and volumes by geography, (ii) patient population and treatment rates with pricing assumptions, or (iii) credible external market research baselines with citations. None are present in the provided context. Under the operating constraints, this prevents producing numbers that would not be complete and accurate.

What is the practical forecast range given generic pressure?

Without externally cited revenue baselines and trial-and-formulation specifics, the only rigorous statement is about directionality under typical generic dynamics:

• Near-term: Stable or modestly declining revenue growth is typical for mature generic beta blockers because price erosion offsets population growth.
• Medium-term: Volume growth can occur, but revenue growth depends on net price trends, supply chain stability, and formulary placement relative to competing beta blockers.
• Risk: Generic competition intensity and pricing pressure are the primary downside drivers. Upside is limited unless a jurisdiction tightens substitution rules or nadolol gains preferential formulary status.

Competitive landscape: what nadolol competes against

Nadolol competes mainly within two categories:

1. Non-selective beta blockers
   These compete directly on therapeutic role (e.g., propranolol-class alternatives).
2. Broader cardiovascular beta blocker alternatives
   Even when selectivity differs (beta-1 selective vs non-selective), prescriber selection can shift due to patient comorbidity profiles and dosing convenience.

Competitive factors that determine share

Factor	What it does to nadolol
Generic price pressure	Compresses net pricing and limits revenue growth
Dosing schedule and patient adherence	Improves or reduces persistence versus alternatives
Formulary preference	Can cause abrupt share shifts between beta blockers
Supply continuity and manufacturing yield	Affects ability to meet demand without backorders

What to watch for in “clinical trials” that actually move the market

For mature generics, the market-moving clinical work usually falls into these buckets:

• Bioequivalence and formulation changes that affect approval and substitution readiness
• Label expansions that broaden covered indication usage
• Combination products that change prescribing behavior

No current, cited nadolol trial register details are available in the provided context to map these items to dates, phases, and outcomes.

Key regulatory and patent implications for market projections

Because the prompt focuses on nadolol, not a specific new product, the relevant commercial expectation is that market supply is already opened widely:

• Patent moat: Generally limited for mature small molecules unless a new formulation, pediatric exclusivity, or combination patent exists in specific countries.
• Lifecycle strategy: Success for generic incumbents usually comes from manufacturing efficiency, product line breadth, and reliable supply rather than clinical novelty.

Investment and R&D implications

Given nadolol’s generic status, most value creation opportunities are operational rather than discovery-driven:

• Supply and cost leadership: If margins are thin, manufacturing reliability and cost control become the differentiators.
• Portfolio construction: Companies often manage beta blocker exposure alongside other cardiovascular generics to stabilize utilization of production lines.
• Formulation advantage: If a firm can win formulary preference via dosing convenience or tolerability profile, share gains can offset price erosion.

Key Takeaways

• Nadolol is a mature, non-selective beta blocker with heavy generic presence, which suppresses pricing power and makes market growth dependent on volume, formulary access, and net pricing.
• No complete, cited current clinical-trials dataset is provided in the context, so a specific “clinical trials update” with phases, endpoints, and timelines cannot be produced without risking inaccuracy.
• A numeric market projection also cannot be produced without cited baseline revenues, patient-treatment rates, and geography-specific assumptions.
• The actionable commercial focus for nadolol is operational: supply reliability, manufacturing cost, and formulary positioning against competing beta blockers.

FAQs

1. Is nadolol still being studied in clinical trials?
Yes, but without cited trial registry details in the provided context, a specific update by study, phase, and outcome cannot be stated.

2. What is the main market driver for nadolol?
Treatment prevalence and prescriber preference within non-selective beta blockade, translated into volume and formulary placement under generic pricing pressure.

3. Does nadolol have patent protection that changes near-term market outlook?
For nadolol as a molecule, patent-driven exclusivity is generally limited because it is widely generic; any meaningful protection would typically be country- and product-specific.

4. What competitive products matter most to nadolol demand?
Non-selective beta blockers and, to a degree, alternative beta blockers selected for patient-specific tolerability and dosing convenience.

5. What would most likely change nadolol’s market trajectory?
Formulary shifts, major supply disruptions, significant label expansions, or a new branded/formulation entrant that alters substitution dynamics.

---

References

[1] FDA. Drug labels and approval history for nadolol (searchable via Drugs@FDA).
[2] EMA. European public assessment reports (EPARs) and related regulatory documents for nadolol (searchable via EMA website).
[3] ClinicalTrials.gov. Nadolol search results and trial registry entries (searchable via ClinicalTrials.gov).